Outcomes With Digoxin in Atrial Fibrillation
[...]the best available evidence on clinical outcomes with digoxin in AF patients comes from post-hoc analyses of clinical trials designed to answer other questions, or from observational studies. The sample size is at least 20 times larger than any prior study on the topic, the sample is drawn from...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2014-08, Vol.64 (7), p.669-671 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 671 |
|---|---|
| container_issue | 7 |
| container_start_page | 669 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 64 |
| creator | Reynolds, Matthew R., MD, MSc |
| description | [...]the best available evidence on clinical outcomes with digoxin in AF patients comes from post-hoc analyses of clinical trials designed to answer other questions, or from observational studies. The sample size is at least 20 times larger than any prior study on the topic, the sample is drawn from many clinical centers around the United States, and the time frame of observation is more contemporary than some previous studies (e.g., the AFFIRM trial). |
| doi_str_mv | 10.1016/j.jacc.2014.04.070 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1552669100</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0735109714041163</els_id><sourcerecordid>3399618991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2190-daf5487a7a5a7d6c5dad00af34ae70357aed0f292e65c2a611c4360427e643f33</originalsourceid><addsrcrecordid>eNpFkN1Kw0AQhRdRsFZfwKuC14kz-9vcCKVaFQq9UPFyWTcb3ZgmdTcV-zY-i0_mhgrCgbk5Z87MR8g5Qo6A8rLOa2NtTgF5DkkKDsgIhZhmTBTqkIxAMZEhFOqYnMRYA4CcYjEi2Wrb227t4uTZ92-Ta__affl2kjTrgzfNz_fCvwTfNKb3XXtKjirTRHf2N8fkaXHzOL_Llqvb-_lsmVmKBWSlqQSfKqOMMKqUVpSmBDAV48YpYEIZV0JFC-qksNRIRMuZBE6Vk5xVjI3JxX7vJnQfWxd7XXfb0KZKnZ6iUhYIkFx077KhizG4Sm-CX5uw0wh6wKJrPWDRAxYNSWoIXe1DLt3_6V3QtvGtt6Z5dzsX_3t0pBr0wwBu4IYcOKJk7BcBhGqv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552669100</pqid></control><display><type>article</type><title>Outcomes With Digoxin in Atrial Fibrillation</title><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Reynolds, Matthew R., MD, MSc</creator><creatorcontrib>Reynolds, Matthew R., MD, MSc</creatorcontrib><description>[...]the best available evidence on clinical outcomes with digoxin in AF patients comes from post-hoc analyses of clinical trials designed to answer other questions, or from observational studies. The sample size is at least 20 times larger than any prior study on the topic, the sample is drawn from many clinical centers around the United States, and the time frame of observation is more contemporary than some previous studies (e.g., the AFFIRM trial).</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2014.04.070</identifier><language>eng</language><publisher>New York: Elsevier Limited</publisher><subject>Cardiac arrhythmia ; Cardiology ; Cardiovascular ; Drug therapy ; Internal Medicine ; Mortality ; Sensitivity analysis ; Studies</subject><ispartof>Journal of the American College of Cardiology, 2014-08, Vol.64 (7), p.669-671</ispartof><rights>American College of Cardiology Foundation</rights><rights>Copyright Elsevier Limited Aug 19, 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2190-daf5487a7a5a7d6c5dad00af34ae70357aed0f292e65c2a611c4360427e643f33</citedby><cites>FETCH-LOGICAL-c2190-daf5487a7a5a7d6c5dad00af34ae70357aed0f292e65c2a611c4360427e643f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Reynolds, Matthew R., MD, MSc</creatorcontrib><title>Outcomes With Digoxin in Atrial Fibrillation</title><title>Journal of the American College of Cardiology</title><description>[...]the best available evidence on clinical outcomes with digoxin in AF patients comes from post-hoc analyses of clinical trials designed to answer other questions, or from observational studies. The sample size is at least 20 times larger than any prior study on the topic, the sample is drawn from many clinical centers around the United States, and the time frame of observation is more contemporary than some previous studies (e.g., the AFFIRM trial).</description><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Cardiovascular</subject><subject>Drug therapy</subject><subject>Internal Medicine</subject><subject>Mortality</subject><subject>Sensitivity analysis</subject><subject>Studies</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpFkN1Kw0AQhRdRsFZfwKuC14kz-9vcCKVaFQq9UPFyWTcb3ZgmdTcV-zY-i0_mhgrCgbk5Z87MR8g5Qo6A8rLOa2NtTgF5DkkKDsgIhZhmTBTqkIxAMZEhFOqYnMRYA4CcYjEi2Wrb227t4uTZ92-Ta__affl2kjTrgzfNz_fCvwTfNKb3XXtKjirTRHf2N8fkaXHzOL_Llqvb-_lsmVmKBWSlqQSfKqOMMKqUVpSmBDAV48YpYEIZV0JFC-qksNRIRMuZBE6Vk5xVjI3JxX7vJnQfWxd7XXfb0KZKnZ6iUhYIkFx077KhizG4Sm-CX5uw0wh6wKJrPWDRAxYNSWoIXe1DLt3_6V3QtvGtt6Z5dzsX_3t0pBr0wwBu4IYcOKJk7BcBhGqv</recordid><startdate>20140819</startdate><enddate>20140819</enddate><creator>Reynolds, Matthew R., MD, MSc</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20140819</creationdate><title>Outcomes With Digoxin in Atrial Fibrillation</title><author>Reynolds, Matthew R., MD, MSc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2190-daf5487a7a5a7d6c5dad00af34ae70357aed0f292e65c2a611c4360427e643f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Cardiovascular</topic><topic>Drug therapy</topic><topic>Internal Medicine</topic><topic>Mortality</topic><topic>Sensitivity analysis</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reynolds, Matthew R., MD, MSc</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reynolds, Matthew R., MD, MSc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes With Digoxin in Atrial Fibrillation</atitle><jtitle>Journal of the American College of Cardiology</jtitle><date>2014-08-19</date><risdate>2014</risdate><volume>64</volume><issue>7</issue><spage>669</spage><epage>671</epage><pages>669-671</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>[...]the best available evidence on clinical outcomes with digoxin in AF patients comes from post-hoc analyses of clinical trials designed to answer other questions, or from observational studies. The sample size is at least 20 times larger than any prior study on the topic, the sample is drawn from many clinical centers around the United States, and the time frame of observation is more contemporary than some previous studies (e.g., the AFFIRM trial).</abstract><cop>New York</cop><pub>Elsevier Limited</pub><doi>10.1016/j.jacc.2014.04.070</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2014-08, Vol.64 (7), p.669-671 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_journals_1552669100 |
| source | Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Cardiac arrhythmia Cardiology Cardiovascular Drug therapy Internal Medicine Mortality Sensitivity analysis Studies |
| title | Outcomes With Digoxin in Atrial Fibrillation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T01%3A10%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20With%20Digoxin%20in%20Atrial%C2%A0Fibrillation&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Reynolds,%20Matthew%20R.,%20MD,%20MSc&rft.date=2014-08-19&rft.volume=64&rft.issue=7&rft.spage=669&rft.epage=671&rft.pages=669-671&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/j.jacc.2014.04.070&rft_dat=%3Cproquest_cross%3E3399618991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552669100&rft_id=info:pmid/&rft_els_id=1_s2_0_S0735109714041163&rfr_iscdi=true |